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Abstract
Background: The objective of this study was to review the effects of adjunctive corticosteroids
on overall mortality and the need for mechanical ventilation in HIV-infected patients with
Pneumocystis jiroveci pneumonia (PCP) and substantial hypoxemia (arterial oxygen partial pressure
<70 mmHg or alveolar-arterial gradient >35 mmHg on room air).
Methods: We conducted a systematic search of the literature for randomised trials published up
to December 2004. Selected trials compared adjunctive corticosteroids with placebo or usual care
in HIV-infected patients with PCP and reported mortality data. Two teams of reviewers
independently evaluated the methodology and extracted data from each primary study.
Results: Six studies were included in the meta-analysis. Risk ratios for overall mortality for
adjunctive corticosteroids were 0.54 (95% confidence interval [CI], 0.38–0.79) at 1 month and 0.67
(95% CI, 0.49–0.93) at 3–4 months of follow-up. Numbers needed to treat, to prevent 1 death, are
9 patients in a setting without highly active antiretroviral therapy (HAART) available and 22 patients
with HAART available. Only the 3 largest trials provided data on the need for mechanical
ventilation with a risk ratio of 0.37 (95% CI, 0.20–0.70) in favour of adjunctive corticosteroids.
Conclusion:  The number and size of trials investigating adjunctive corticosteroids for HIV-
infected patients with PCP is small, but our results suggest a beneficial effect for patients with
substantial hypoxemia.
Background
With the introduction of highly active antiretroviral ther-
apy (HAART) more than a decade ago, the incidence of
Pneumocystis jiroveci pneumonia (PCP) [1] has decreased
significantly in the Western hemisphere. However, PCP
still remains the most common opportunistic infection in
patients infected with the human immunodeficiency virus
(HIV) [2]. Among patients with HIV infection and PCP
the mortality rate is 10 to 20% during the initial infection
and increases substantially with the need for mechanical
ventilation [3]. In 1990 an expert panel recommended the
use of corticosteroids for HIV-infected patients with PCP
and substantial hypoxemia (initial arterial oxygen partial
pressure of <70 mmHg or alveolar-arterial gradient >35
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mmHg on room air) based on the evidence from five ran-
domised controlled trials [4]. This consensus statement
still represents the basis of current treatment guidelines
[5]. However, at the time this statement was made, one
trial was not yet completed [6], two trials were stopped
prematurely [7,8], and one trial was not published in full
[9]. In 1992 a systematic review qualitatively summarised
the same incomplete data [10].
We present an updated systematic review and meta-analy-
sis of randomised controlled trials to assess the magnitude
of effects of adjunctive corticosteroid therapy on overall
mortality and the need for mechanical ventilation in HIV-
related PCP. In addition, we provide numbers needed to
treat that may serve as estimates for the expected benefit
of adjunctive corticosteroid therapy in the presence and
absence of HAART.
Methods
Search for relevant studies
We searched MEDLINE (January 1985 – December 2004),
EMBASE (January 1985 – December 2004) and the
Cochrane Library (issue 4, 2004) without language restric-
tions to identify randomised controlled trials that com-
pared adjunctive corticosteroids to control in HIV-
infected patients with PCP. We used the terms steroid*,
corticosteroid*, glucocorticoid*, pneumocystis, PCP,
*carinii, *jiroveci as text words and Glucocorticoids,
Adrenal Cortex Hormones, Steroids, Pneumocystis Infec-
tions, Pneumocystis jiroveci, and Pneumonia, Pneumo-
cystis as Medical Subject Headings. We restricted the
search to articles indexed as randomised controlled trials
(publication type) or drug therapy (subject heading) or
those that included the words random* or placebo in
their titles or abstracts. We further reviewed the reference
Flow diagram of trials Figure 1
Flow diagram of trials. RCT, randomised controlled trial.
8 potentially relevant RCTs identified
and screened for retrieval 
8 potentially relevant RCTs identified
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8 RCTs retrieved for more detailed 
evaluation
8 RCTs retrieved for more detailed 
evaluation
2 RCTs excluded, with 
reasons: Follow-up<1month
(n=1), subgroup analysis of 
included trial (n=1).
2 RCTs excluded, with 
reasons: Follow-up<1month
(n=1), subgroup analysis of 
included trial (n=1). 6 potentially appropriate RCTs to be 
included in the meta-analysis 
6 potentially appropriate RCTs to be 
included in the meta-analysis 
6 RCTs included in the meta-analysis 6 RCTs included in the meta-analysis
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lists from previously published overviews [4,10], we
searched UptoDate version 2005 and Clinical Evidence
Concise (issue 12, 2004), contacted experts of the field,
and searched reference lists of identified publications for
citations of additional relevant articles.
Study selection and data abstraction
Trials were considered eligible for this meta-analysis if
they compared corticosteroids to placebo or usual care in
HIV-infected patients with PCP in addition to baseline
treatment with trimethoprim-sulfamethoxazole, penta-
midine or dapsone-trimethoprim, used random alloca-
tion, and reported mortality data. We excluded trials in
patients with no or mild hypoxemia (arterial oxygen par-
tial pressure >70 mmHg or an alveolar-arterial gradient
<35 mmHg on room air) and trials with a follow-up of
less than 30 days.
Two teams of investigators (MB/HCB and RB/HF)
assessed study eligibility and quality blinded to one
another's rating and resolved any disagreement by con-
sensus. Data of eligible trials were abstracted in duplicate.
We assessed the quality of included trials with respect to
concealment of treatment allocation; blinding of patients,
caregivers or assessors of clinical outcomes; performance
of a sample size calculation; and if the trial was stopped
Funnel plot to evaluate the presence of a publication bias in trials investigating adjunctive corticosteroids for pneumocystis  jiroveci pneumonia in HIV-infected patients Figure 2
Funnel plot to evaluate the presence of a publication bias in trials investigating adjunctive corticosteroids for pneumocystis 
jiroveci pneumonia in HIV-infected patients. The funnel graph plots the log of the treatment odds ratio against the standard 
error (s.e.) of the log odds ratio (an indicator of sample size). Open circles represent trials included in the meta-analysis. The 
line in the centre indicates the summary log odds ratio. In the absence of a publication bias, the log odds ratio estimates from 
smaller trials are expected to be scattered above and below the summary estimate, producing a symmetric triangular or funnel 
shape. When smaller trials with larger log odds ratios are missing, the funnel plot appears asymmetric and may indicate the 
presence of a publication bias. In our systematic review the funnel plot looks symmetric. The Egger test for publication bias was 
not statistically significant (P = 0.91).
Begg's funnel plot with pseudo 95% confidence limits
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Table 1: Characteristics of included trials
Author 
(year) 
reference
Diagnosis of 
PCP
Baseline 
treatment 
for PCP
Oxygenation 
entry criteria
Corticoid 
(route)/initial 
daily dose/
duration 
(days)
Interval 
(max.) *
Blinding 
patients/care 
givers/
assessors
Concealed 
allocation/n 
centres
Sample size 
calculation/
stopped early
Randomised 
individuals to 
I/C
Total deaths 
in I/C
Clement et al. 
(1989) [9]
BAL, sputum 88% TMP-SMX, 
12% 
Pentamidine
PaO2<51 
mmHg (room 
air)
Methylpredniso
lon (IV)/240 
mg/8 d
Unlimited Yes/Yes/
Unclear
Unclear/1 Unclear/No 19/22 9/9 at 56 days
Montaner et al. 
(1990) [8]
BAL TMP-SMX, 
Pentamidine, 
Dapsone-TMP
85–90% O2-
Saturation †
Prednisone 
(oral)/60 mg/7 
d with 14 d 
tapering
48 h Yes/Yes/
Unclear
Yes/1 Yes/Yes 18/19 1/0 at 30 days 
2/1 at 90 days
Bozzette et al. 
(1990) [16]
75% BAL, 15% 
sputum + 
presumed
80% TMP-SMX, 
18% 
Pentamidine, 
2% Dapsone-
TMP
Hypoxemia 
ratio >75 ‡
Prednisone 
(oral)/80 mg/21 
d or as baseline 
treatment
36 h No/No/Unclear Yes/6 Yes/No 123/128 13/28 at 31 
days 20/33 at 
84 days
Gagnon et al. 
(1990) [7]
BAL, biopsy, 
sputum
TMP-SMX PaO2<75 
mmHg (35% 
oxygen)
Methylpredniso
lon (IV)/160 
mg/7–10 d
72 h Yes/Yes/
Unclear
Unclear/1 Yes/Yes 12/11 3/9 at 28 days 
5/9 at 120 days
Nielsen et al. 
(1992) [6]
BAL, biopsy TMP-SMX PaO2<67.5 
mmHg (room 
air)
Methylpredniso
lon (IV)/2 mg/
kg/10 d
24 h No/No/Unclear Unclear/3 Unclear/Yes 30/29 2/9 at 34 days 
4/9 at 90 days
Walmsley et al. 
(1995) [19]
BAL, biopsy, 
sputum
82% TMP-SMX, 
17% 
Pentamidine, 
1% Dapsone-
TMP
PaO2<70 
mmHg (room 
air) §
Methylpredniso
lon (IV)/80 mg/
10 d
24 h Yes/Yes/
Unclear
Yes/3 Yes/No 40/38 4/6 at 35 days
Abbreviations: PCP, Pneumocystis jiroveci pneumonia; n, number; I/C, intervention/control group; BAL, bronchoalveolar lavage; TMP, trimethoprim; SMX, sulfamethoxazole; IV, intravenous.
* Maximal interval between initiation of baseline treatment for Pneumocystis jiroveci pneumonia and initiation of corticosteroid.
† Or 5% decrease on exercise.
‡ PaO2 divided by fraction of inspired oxygen.
§ Or alveolar-arterial oxygen gradient >40 mmHg if arterial blood gases could not be assessed on room air.BMC Infectious Diseases 2005, 5:101 http://www.biomedcentral.com/1471-2334/5/101
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Summary estimates for overall mortality at 1 month (A) and 3–4 months (B) follow-up Figure 3
Summary estimates for overall mortality at 1 month (A) and 3–4 months (B) follow-up. The Cochran Q test for heterogeneity. 
I2 as a measure of inconsistency (in percent). CI indicates confidence interval; UI, uncertainty interval.
Risk ratio
.1 1 10
 % Weight
 Risk ratio
 (95% CI)
 1.16 (0.58,2.31)  Clement (1989)  13.7
 3.16 (0.14,72.84)  Montaner (1990)   0.8
 0.48 (0.26,0.89)  Bozzette (1990)  45.0
 0.31 (0.11,0.85)  Gagnon (1990)  15.4
 0.21 (0.05,0.91)  Nielsen (1992)  15.0
 0.63 (0.19,2.07)  Walmsley (1995)  10.1
 0.54 (0.38,0.79)  Overall (95% CI)
Mortality at
1 month follow-up
Favours corticosteroids Favours control Heterogeneity P = 0.12
Inconsistency I
2= 43%
[95% UI, 0-79%]
A
Risk ratio
.1 1 10
% Weight
Risk ratio
(95% CI)
1.16 (0.58,2.31)  Clement (1989) 12.6
2.11 (0.21,21.36)  Montaner (1990)  1.5
0.63 (0.38,1.04)  Bozzette (1990) 48.7
0.51 (0.25,1.05)  Gagnon (1990) 14.2
0.43 (0.15,1.24)  Nielsen (1992) 13.8
0.63 (0.19,2.07)  Walmsley (1995)  9.3
0.67 (0.49,0.93)  Overall (95% CI)
Mortality at
3-4 months follow-up
Heterogeneity P = 0.50
Inconsistency I
2 = 0%
[95% UI, 0-79%]
Favours corticosteroids Favours control
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early [11]. The main endpoint for benefit of adjunctive
corticosteroid therapy was overall mortality. A secondary
endpoint was the need for mechanical ventilation.
Statistical analysis
All analysis was according to the intent-to-treat principle.
We pooled treatment effects across studies and calculated
a weighted average risk ratio of overall mortality in the
treatment and control groups by using a random effects
model. We investigated the presence of publication bias
by means of funnel plots [12]. We tested for heterogeneity
with the Cochran Q test and measured inconsistency (I2;
the percentage of total variance across studies that is due
to heterogeneity rather than chance) of treatment effects
across studies [13,14]. We carried out sensitivity analyses
to examine treatment effects according to quality compo-
nents of trials, and if publication was as a peer-reviewed
article or just in abstract form. Numbers needed to treat
were calculated by multiplying the mean relative risk
reduction with an initial mean baseline risk [15]. All sta-
tistical analyses were performed using Stata 8.2 (Stata-
Corp, College Station, Tex).
Results
We identified 8 trials [6-9,16-19] that met our inclusion
criteria (Figure 1). We excluded one trial [17] because it
investigated only patients with mild hypoxemia and had
a very short follow-up of only 3 days, and another trial
[18] which turned out to be a subgroup analysis of a larger
included trial [8] [see Additional file 1]. In total, there
were 242 individuals in the intervention and 247 individ-
uals in the control groups. The Funnel plot indicated no
evidence for a publication bias (Figure 2). Characteristics
of included trials are provided in Table 1.
Overall mortality
Risk ratios for overall mortality were significantly reduced
for adjunctive corticoids at 1 month (0.54;95% CI, 0.38–
0.79) and at 3–4 months (0.67;95% CI, 0.49–0.93) of fol-
low-up (Figure 3). We found some evidence for heteroge-
neity among trials at 1 month (test of heterogeneity, P =
0.12; I2 = 43% [95% uncertainty interval [UI], 0%–78%])
whereas at 3–4 months treatment effects looked more
homogenous (P = 0.46; I2 = 0% [95% UI, 0%–75%]. In a
sensitivity analysis heterogeneity was considerably
reduced when the analysis was limited to trials with early
(<3 days) adjunctive corticosteroids that were published
in full, i.e. excluding Clement et al. [9] (summary risk
ratio for mortality at 1 month: 0.45 (95% CI, 0.29–0.70),
heterogeneity P = 0.49; I2 = 0% [95% UI, 0%–79%]). In
further sensitivity analyses for the mortality endpoint at 1
month summary risk ratios were 0.55 (95% CI, 0.32–
0.93) in trials that reported concealed allocation
[8,16,19], 0.74(95% CI, 0.45–1.21) in trials reporting
blinding of patients and care-givers [7-9,19], and 0.64
(95% CI, 0.42–0.98) in trials not prematurely halted
[9,16,19].
Need for mechanical ventilation
Reliable data on the need for mechanical ventilation was
only available for the 3 largest trials [6,16,19]. Again, the
risk ratio for this endpoint was largely reduced in the
group with early adjunctive corticosteroids (0.37;95% CI,
0.20–0.70; P = 0.40; I2 = 0% [95% UI, 0%–90%]).
Discussion
This systematic review of 6 randomised controlled trials in
HIV-infected patients with PCP and substantial hypox-
emia found a significant relative risk reduction of death
for adjunctive corticosteroids of 46% at 1 month and of
33% at3–4 months. The average-weighted mean mortality
in control groups of included trials at one month was
25%. This initial mortality-rate of 25% can be assumed in
settings where HAART is not available which is still the
case for most developing countries [20]. In this situation
we estimated that 9 (95% CI, 6–19) HIV-infected patients
with PCP have to be treated early with adjunctive corticos-
teroids to prevent 1 death during the first month after PCP
diagnosis. In Western countries, where HAART is widely
available, the respective number to treat was estimated to
be 22 (95% CI, 16–48) patients assuming an initial mor-
tality rate of 10% [21]. With regard to the need for
mechanical ventilation the risk reduction for adjunctive
corticosteroids was even greater in the investigated patient
population, but the number of trials was small (n = 3).
Our study has several strengths and limitations. We con-
ducted an extensive literature search to retrieve all eligible
trials. However, formal testing for publication bias was
not very powerful because of a relatively small number of
included trials. Even with a symmetric looking funnel
plot, such bias cannot be ruled out. Moreover, with a
small number of included trials the uncertainty interval
for the inconsistency among trials may not be very
informative [13]. We focused mainly on mortality data
that may be less prone to ascertainment bias, and we ana-
lysed the data according to the intent-to-treat principle to
get more conservative estimates. Finally, the trials
included in this meta-analysis used different corticoster-
oid regimen. So far, neither the dosing nor the length and
tapering schedule of corticosteroids has been addressed
adequately in randomised trials. In current recommenda-
tions [5] the corticosteroid schedule of the largest trial
[16] was adapted.
There has been some concern among physicians treating
patients with AIDS that further immunosuppression due
to corticosteroid therapy could accelerate the onset of
other HIV-related opportunistic complications [22,23].
However, with the exception of an increase in muco-cuta-BMC Infectious Diseases 2005, 5:101 http://www.biomedcentral.com/1471-2334/5/101
Page 7 of 8
(page number not for citation purposes)
neous herpes simplex infection episodes [16], adjunctive
corticosteroids were not associated with an increase in
opportunistic complications in any of the included trials.
A large cohort study which used a standard 21-day taper-
ing course of adjunctive corticosteroids found no differ-
ence in the risk of AIDS-related complications apart from
an increase in esophageal candidiasis [24].
It is possible that adjunctive corticosteroids are also bene-
ficial for HIV-infected patients with mild hypoxemia due
to PCP [17]. However, in this situation the short term
mortality is low and possible unfavourable effects of cor-
ticosteroids might outweigh the benefits. Moreover, corti-
costeroids might also be beneficial for non-HIV-infected
patients with severe PCP [25], but evidence from ran-
domised controlled trials is still lacking.
Conclusion
This meta-analysis confirmed and quantified the benefit
of adjunctive corticosteroid therapy in HIV-infected
patients with moderate-severe PCP. We estimated a rela-
tive risk reduction for overall mortality of 46% at 1 month
and 33% at 3–4 months. We calculated numbers needed
to treat of 9 patients for settings without HAART, and 22
patients with HAART available to prevent 1 death. Our
results underline the conclusions of the early released
consensus statement [4], and support current recommen-
dations for the management of PCP in HIV-infected
patients [5].
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